MIST News and Press, Milestone Pharmaceuticals Inc. From 03/29/23

2023-03-29 16:59:22 ET Milestone Pharmaceuticals press release ( NASDAQ: MIST ): Q4 GAAP EPS of -$0.31. Revenue of $3.5M. As of December 31, 2022, Milestone had cash, cash equivalents, and short-term investments of $64.6 million, compared to $114.1 million as of Decemb...

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Corporate Update Canada NewsWire - Year-end cash resources, together with $125 million proceeds from March 2023 strategic financing, expected to fund operati...

2023-03-28 12:59:07 ET Milestone Pharma ( NASDAQ: MIST ) is trading 11.1% higher after a $125M strategic funding agreement with RTW Investments and certain of its affiliates. The company said proceeds from the financing, together with $64.6M of cash as of December 31, are ...

Milestone Pharmaceuticals Announces $125 Million Strategic Financing with RTW Investments to Support the Advancement of Etripamil for PSVT Canada NewsWire - Proceeds from strategic financing together with year-end cash resources expected to fund operations into mid-2025 includ...

Milestone Pharmaceuticals Progresses Clinical and Regulatory Activities for Etripamil in Patients with Paroxysmal Supraventricular Tachycardia Canada NewsWire - Both the NODE-303 and RAPID-extension studies are complete - Following FDA feedback, Etripamil NDA is on-tra...

Milestone Pharmaceuticals to Host Virtual Commercial Deep-Dive Event on Etripamil for PSVT Canada NewsWire Conference call and webcast on Tuesday, December 6, 2022 at 1:00 p.m. ET MONTREAL and CHARLOTTE, N.C. , Nov. 29, 2022 /CNW...

Milestone Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference Canada NewsWire MONTREAL and CHARLOTTE, N.C. , Nov. 22, 2022 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company fo...

Penny Stocks To Buy According To 5 Wall Street Analysts Today we look at a handful of penny stocks to buy, according to Wall Street analysts. It’s an interesting phenomenon when traders use ratings as part of their research methodologies. Sure, the so-called “smart mon...

Milestone Pharmaceuticals press release ( NASDAQ: MIST ): Q3 GAAP EPS of -$0.34 beats by $0.07 . Revenue of $1.5M (-98.8% Y/Y). For further details see: Milestone Pharmaceuticals GAAP EPS of -$0.34 beats by $0.07, revenue of $1.5M

Milestone Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Corporate Update Canada NewsWire - Phase 3 RAPID trial of etripamil in patients with PSVT achieved primary efficacy endpoint; safety and tolerability data from repeat dose ...